News Overview

Alentis Therapeutics


Alentis Therapeutics develops breakthrough treatments for fibrotic diseases.The pipeline includes highly specific antibodies against Claudin-1, a novel key target in fibrosis and several cancers. The lead asset will start clinical trials in 2021.Unlike most therapies that address the disease indirectly, Alentis’ pioneering approach aims at directly reversing disease progression.Alentis is headquartered in Basel, Switzerland with a subsidiary for R&D in Strasbourg, France.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.